A therapeutic α particle payload imparts cytotoxic high linear energy therapy and has been shown to be clinically beneficial in treating leukemia when delivered by Lintuzumab.18,19 Surprisingly, both radiolabeled [225Ac]αMSH-PEG-Cy5-C′ (“hot”) and unlabeled αMSH-PEG-Cy5-C′ dots (cold) similarly cue significant changes in the TME immune cell signatures. The gene discussed is STAMBP; the disease is leukemia.